Superior Genomics, Inc. — SEC Form D Filing

Superior Genomics, Inc. filed an SEC Form D on August 14, 2026, reporting $508K raised in Health Technology.

Form D filing details

Filing
SEC Form D
Filing date
August 14, 2026
Amount reported
$508K
Round stage
Pre-Seed
Industry
Health Technology
Website
https://superiorgenomics.com/

What the company does

Securities: Simple Agreement for Future Equity (SAFE). Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Millions of people globally are living with depression and bipolar disorder, and there is a need for objective tests to accurately diagnose these mental health conditions.

Solution

Superior Genomics is developing diagnostic blood tests that utilize discovered gene expression bioprofiles to accurately diagnose depressive symptoms as Bipolar Disorder or Major Depressive Disorder.

Why now

Increasing awareness and acceptance of mental health issues, coupled with the impact of recent global events, highlights the need for objective and accurate diagnostic tools in mental healthcare.

Verdict

This cleared because investors saw a direct diagnostic application of genomics to a widespread, underserved mental health problem, not because the technology itself was novel or proprietary outside of its specific application. Investors were implicitly betting on early clinical validation demonstrating superior diagnostic accuracy and the potential for a clear reimbursement pathway. The limited upside stemmed from the long, expensive regulatory path and the highly specialized market entry, which restricted immediate scaling beyond niche psychiatric practices.

Source: SEC EDGAR Form D filing